RNA interference (RNAi) technology is the genetic medicines modality with the highest degree of human validation. This powerful pharmaceutical technology has experienced a rapid transition from Nobel Prize to marketed products that reversibly silence disease-promoting genes. SanegeneBio operates under the singular vision that RNAi will become standard-of-care for a broad range of disease indications, with the potential to impact longevity and quality-of-life for many.
The medical, scientific and patient communities are now witnessing RNAi at a crossroads – from benefitting small populations with genetically-defined diseases to benefitting large numbers of patients with chronic metabolic disorders. SanegeneBio has developed proprietary nucleic acid and targeted delivery technology to enable safe, effective and durable RNAi medicines which can be self-administered as infrequently as two times per year.
PK Modulation
Receptor Affinity
Intracellular Trafficking
Small Molecules
Peptides
Antibodies
We’re advancing a pipeline of best-in-class therapeutics targeting obesity and metabolic disorders, complement-mediated immune diseases, and cardiovascular diseases.
